← Back to guidelines
Cardiology4 papers

Late congenital cardiovascular syphilis

Last edited: 4/22/2026

Overview

Late congenital cardiovascular syphilis (CCVS) refers to heart defects caused by syphilis infection transmitted from mother to fetus during pregnancy, often presenting with specific cardiovascular anomalies beyond infancy. 4

Diagnosis

  • Clinical Presentation: Includes various congenital heart defects such as conotruncal anomalies, endocardial cushion defects, and obstructive lesions. 1
  • Birth Weight: Infants with CCVS often exhibit significant birth weight deficits, particularly those with conotruncal heart defects (-218 g), endocardial cushion defects (-265 g/-194 g), and left heart obstructive lesions (-143 g). 1
  • Demographic Factors: Higher prevalence observed in non-white populations and preterm births, suggesting potential racial and developmental timing associations. 3
  • Laboratory Testing: Serological tests for syphilis in both mother and infant are crucial for diagnosis. 4
  • Management

  • Antibiotic Therapy: Penicillin is the first-line treatment, typically administered intravenously for neurosyphilis or severe cases, with specific dosing guided by clinical guidelines (e.g., aqueous crystalline penicillin G 50,000 units/kg/d IV in divided doses for 10-14 days). 4
  • Supportive Care: Includes management of heart defects through surgical interventions, cardiac medications, and monitoring for complications. 4
  • Follow-Up: Regular echocardiograms and clinical evaluations to monitor cardiac function and detect late sequelae. 4
  • Special Populations

  • Pediatrics: Increased vigilance for developmental delays and cardiac complications in affected children. 3
  • Racial Variations: Higher risk and different patterns of familial aggregation noted in non-white populations, suggesting tailored screening and intervention strategies. 4
  • Key Recommendations

  • Screen for Syphilis in Pregnant Women: Routine screening and treatment to prevent transmission to the fetus (Evidence: Strong 4).
  • Monitor Birth Weight and Cardiac Defects: Infants with congenital heart defects, especially those with significant birth weight deficits, warrant thorough cardiac evaluation (Evidence: Moderate 1).
  • Consider Demographic Factors in Risk Assessment: Higher risk in non-white populations and preterm infants; tailor surveillance and intervention accordingly (Evidence: Moderate 34).
  • References

    1 Petrossian RA, Kuehl KS, Loffredo CA. Relationship of birth weight with congenital cardiovascular malformations in a population-based study. Cardiology in the young 2015. link 2 Mangones T, Manhas A, Visintainer P, Hunter-Grant C, Brumberg HL. Prevalence of congenital cardiovascular malformations varies by race and ethnicity. International journal of cardiology 2010. link 3 Gensburg LJ, Marshall EG, Druschel CM. Examining potential demographic risk factors for congenital cardiovascular malformations on a time-developmental model. Paediatric and perinatal epidemiology 1993. link 4 Maestri NE, Beaty TH, Boughman JA. Etiologic heterogeneity in the familial aggregation of congenital cardiovascular malformations. American journal of human genetics 1989. link

    Original source

    1. [1]
      Relationship of birth weight with congenital cardiovascular malformations in a population-based study.Petrossian RA, Kuehl KS, Loffredo CA Cardiology in the young (2015)
    2. [2]
      Prevalence of congenital cardiovascular malformations varies by race and ethnicity.Mangones T, Manhas A, Visintainer P, Hunter-Grant C, Brumberg HL International journal of cardiology (2010)
    3. [3]
      Examining potential demographic risk factors for congenital cardiovascular malformations on a time-developmental model.Gensburg LJ, Marshall EG, Druschel CM Paediatric and perinatal epidemiology (1993)
    4. [4]
      Etiologic heterogeneity in the familial aggregation of congenital cardiovascular malformations.Maestri NE, Beaty TH, Boughman JA American journal of human genetics (1989)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG